Left Ventricular Dysfunction, Menopause
Conditions
Brief summary
The purpose of this study is to compare left ventricular stroke volume and heart rate responses to bursts of SNA between PMF using, and not using, MHT.
Interventions
Taken in accordance with standard clinical practice, administered for a minimum duration of eight weeks.
Sponsors
Mayo Clinic
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
45 Years to 60 Years
Inclusion criteria
• \>45-60\< years of age
Exclusion criteria
* Male sex * Females between STRAW+10 stages -5 and 0 * PMF in STRAW+10 stage +2 * PMF using oral hormone therapy * Females who entered menopause due to a surgical procedure or in response to pharmacotherapy (e.g., gonadotrophin releasing hormone agonists or chemotherapy) * Heart disease such as hypertropic cardiomyopathy, congenital abnormalities, chronic heart failure, valve disease, and a history of myocardial infarction * Medications that impact the central nervous system including selective serotonin reuptake inhibitors, anxiolytics, sedatives, anticholinergic agents, dopamine, amphetamines, or wake-promoting agents (e.g., modafinil). Other medications will be evaluated on an individual basis by the PI. * Cardiovascular medications is also an exclusion criterion which includes those acting on the renin-angiotensin-aldosterone axis, adrenergic receptor antagonists, diuretics, nitrates, and calcium channel antagonists. Other medications will be evaluated on an individual basis by the PI. * Pregnancy * COPD * Diabetes * CKD * Raynaud's phenomenon * Sleep disorders * Shift workers * BMI ≥40.0kg/m2 * Use of nicotine-containing products within the two years preceding study visits * Active cancer treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Left ventricular stroke volume | Baseline | Left ventricular stroke volume is the amount of blood pumped from the left ventricle per heartbeat (mL) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ventriculo-Arterial (VA) coupling | Baseline | Ventriculo-Arterial (VA) coupling will be measured as the ratio of end-systolic elastance (Ees) to arterial elastance (Ea). |
Countries
United States
Contacts
CONTACTJoshua Bock, Ph.D.
PRINCIPAL_INVESTIGATORJoshua Bock, Ph.D.
Mayo Clinic
Outcome results
None listed